Addressing the challenge of resistance to ALK inhibitors
Dr Robert Doebele explores the mechanisms of resistance to ALK inhibitors, focusing on acquired resistance. He reviews the resistance profiles of ALK inhibitors, as well as summarising the impact of treatment resistance on patient outcomes.view bio and disclosures 2/3 Next Chapter
Overview & Learning Objectives
In this activity, Dr Robert Doebele, an internationally renowned expert in lung cancer, discusses the latest developments in the anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) treatment landscape, including data on ALK-inhibitor intracranial efficacy, and how improved understanding of acquired resistance mechanisms and refined molecular testing techniques may optimize outcomes for patients with ALK-positive NSCLC.
This activity has been jointly provided by Oakstone Publishing and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity has been designed to meet the educational needs of oncologists, oncology nurses and other healthcare practitioners who care for patients with ALK-positive NSCLC.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Dr Robert Doebele Discloses: Consultant/Advisory Boards fees from Anchiano Therapeutics, AstraZeneca, Blueprint Medicines, Genentech/Roche, GreenPeptide Co., Ltd., Rain Therapeutics Inc. and Takeda. Stockholder in Rain Therapeutics Inc. Licensing of IP with Black Diamond, Foundation Medicine, Genentech, Pearl River, Rain Therapeutics and Voronol.
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Alison Scott, PhD has no financial interests/relationships or affiliations in relation to this activity.
Requirements for successful completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AME). European physicians interested in converting 0.5 AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Date of original release: July 24, 2020. Date credits expire: July 24, 2021.
After watching this activity participants should be better able to:
- Summarize the central nervous system (CNS) efficacy data for ALK inhibitors in the first- and second-line settings for patients with ALK-positive NSCLC
- Evaluate the mechanisms of acquired resistance to ALK inhibitors in patients with ALK-positive NSCLC
- Discuss the most appropriate approach to molecular testing for patients with ALK-positive NSCLC
Faculty & Disclosures
Dr Robert Doebele
University of Colorado School of Medicine, Aurora, CO, USA
Robert Doebele is Associate Professor of Medicine in the Division of Medical Oncology at the University of Colorado School of Medicine. Dr Doebele earned his degree in Molecular Biology from Princeton University and his MD/PhD from the University of Pennsylvania School of Medicine, before training in Medical Oncology at the University of Chicago.
Dr Robert Doebele discloses: Consultant/Advisory Boards fees from Anchiano Therapeutics, AstraZeneca, Blueprint Medicines, Genentech/Roche, GreenPeptide Co., Ltd., Rain Therapeutics Inc. and Takeda. Stockholder in Rain Therapeutics Inc. Licensing of IP with Black Diamond, Foundation Medicine, Genentech, Pearl River, Rain Therapeutics and Voronol.